A further detailed characterisation revealed specific targetable genetic alterations, such as ELF3 mutations and FGFR2 gene fusions,89 with variations in mutation types and frequencies across BTC subtypes suggesting a role for immunomodulatory treatments in hypermutated tumours. Here, FGFR2 is linked to neoplasm.